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Abstract 
There is increasing evidence linking neuroinflammation to many neurological 
disorders including Alzheimer's disease (AD), however its exact contribution to disease 
manifestation and/or progression is poorly understood. Therefore, a need exists to find new 
ways of investigating neuroinflammation in both health and disease. Here we investigate 
cognitive decline, neuroinflammatory and other pathophysiological changes in the 
APPswe×PS1Δe9 transgenic mouse model of AD. Transgenic (TG) mice were compared to 
C57BL/6 wild type (WT) mice at 6, 12 and 18 months of age. Neuroinflammation was 
investigated by [18F]DPA-714 positron emission tomography and myo-inositol levels using 1H 
magnetic resonance spectroscopy (MRS) in vivo. Neuronal and cellular dysfunction was 
investigated by looking at N-acetylaspartate (NAA), choline containing compounds, taurine 
and glutamate also using MRS. Cognitive decline was first observed at 12m-old in the TG 
mice as assessed by working memory tests. A significant increase in [18F]DPA-714 uptake 
was seen in the hippocampus and cortex of 18m-old TG mice when compared to age 
matched WT mice and 6m-old TG mice. No overall effect of gene was seen on metabolite 
levels; however a significant reduction in NAA was observed in 18m-old TG mice when 
compared to WT. In addition, age resulted in a decrease in glutamate and an increase in 
choline levels. Therefore we can conclude that increased neuroinflammation and cognitive 
decline are observed in TG animals, whereas NAA alterations occurring with age are 
exacerbated in the TG mice. These results support the role of neuroinflammation and 
metabolite alteration in AD and in aging. 
Key words: Alzheimer’s disease, animal model, neuroinflammation, positron emission 
tomography, magnetic resonance spectroscopy. 
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Introduction 
Alzheimer’s disease (AD) is the most common form of dementia which has become a 
huge socio-economic burden due to an increased aging population. Despite considerable 
research, the mechanisms leading to its manifestation remain unclear. AD is defined 
pathologically by amyloid plaques (Aβ), neurofibrillary tangles (NFTs) and neuronal loss 
(Braak & Braak 1991); however the aetiology remains elusive. Hence, a need exists to find 
biomarkers that can help understand disease progression and mechanisms, aid diagnosis 
and track the efficacy of therapeutic interventions. 
AD is a multifactorial disease associated with complex neuronal and 
neuroinflammatory alterations (Heneka et al. 2015, Perry & Holmes 2014, Rubio-Perez & 
Morillas-Ruiz 2012, Mhatre et al. 2015, Halliday et al. 2000). Activated microglia have been 
shown to surround amyloid plaques (Haga et al. 1989) ex vivo and increased inflammatory 
cytokine expression is observed post-mortem in brain and in vivo in the serum and CSF of 
AD and patients with mild cognitive impairment (MCI) (Varnum & Ikezu 2012, Rubio-Perez & 
Morillas-Ruiz 2012, Swardfager et al. 2010, Forlenza et al. 2009, Westin et al. 2012). In 
addition, treatments which experimentally reduce pro-inflammatory cytokines have been 
shown to improve memory performance (Song et al. 2013, Lee et al. 2013), suggesting 
increased inflammation could contribute to memory impairments seen in AD. 
The ability to accurately assess neuroinflammation in vivo is important to our 
understanding of the impact it has in AD. The discovery that translocator receptor 18kDa 
(TSPO) expression is upregulated on activated microglial cells (Papadopoulos et al. 2006) has 
enabled the generation of TSPO radio-ligands to image neuroinflammation in vivo using 
positron emission tomography (PET). TSPO expression in the brain is mainly restricted to 
endothelial cells and activated microglia, and is low in healthy brain tissue where 
inflammation is absent (Scarf & Kassiou 2011, Papadopoulos et al. 2006); therefore TSPO 
PET permits the identification and tracking of region-specific neuroinflammation throughout 
disease progression. Although it is important to note that TSPO is also expressed endothelial 
cells and hence in blood vessels (Turkheimer et al. 2007). 
PK11195, a TSPO ligand, has been successfully labelled with 11C and has shown good 
correlation to microglial activation ex vivo (Venneti et al. 2009), however contradictory 
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reports exist regarding the detection of neuroinflammation in AD using [11C]PK11195 
imaging. Some studies have demonstrated increased [11C]PK11195 binding in AD and MCI 
patients (Edison et al. 2008, Yokokura et al. 2011), whereas others have reported no 
differences in any regions between patients and age matched controls (Wiley et al. 2009, 
Schuitemaker et al. 2013). Short half-life, low signal to noise ratio, high non-specific binding 
and modelling issues may have contributed to these contradictory results (Boutin & Pinborg 
2015, Varrone & Lammertsma 2015), hence new generation tracers with improved affinities 
and kinetics such as [18F]DPA-714 (Chauveau et al. 2009, Boutin et al. 2013, Doorduin et al. 
2009, James et al. 2008) have been developed to assess. Recently, using [18F]DPA-714, 
Hamelin et al. have demonstrated that AD patients with slower cognitive decline had higher 
level of neuroinflammation (Hamelin et al. 2016), hypothesising that neuroinflammation 
may also exert neuroprotective functions early in the disease. However, this is the first in 
vivo study showing a positive correlation between neuroinflammation and cognitive decline, 
suggesting a potential beneficial role for neuroinflammation in AD. However this needs to 
be further investigated as TSPO expression is only a surrogate marker of microglial 
activation in a broad sense and does not provide information on the functional phenotype 
of activated microglia. Similarly, TSPO expression has been reported to be increased with 
ageing (Gulyas et al. 2011, Kumar et al. 2012) but the role and meaning of this potential 
increase with age is yet to be fully understood. 
Similarly, magnetic resonance spectroscopy (MRS), a method that allows the 
detection of metabolite profiles in vivo, can also be used to investigate neuroinflammation 
through measurement of myo-inositol (mI) levels. mI has been suggested to be a glial 
specific marker (Brand et al. 1993) indicative of increased gliosis. Although increased levels 
of mI have been repeatedly reported in AD and MCI subjects in regions associated with 
degeneration in AD (Parnetti et al. 1997, Murray et al. 2014, Kantarci 2007, Shinno et al. 
2007, Shiino et al. 2012, Foy et al. 2011, Rose et al. 1999), evidence suggests that mI does 
not necessarily correlate with increased microglial activation ex vivo (Murray et al. 2014, 
Pardon et al. 2016) and may be more directly associated with plaque load. MRS can also 
measure other metabolites of interest related to neuronal function including N-
acetylaspartate (NAA), glutamate (Glu), taurine (Taur), total choline (tCho) and creatine + 
phosphocreatine (Cr). NAA is a neuronal marker (Birken & Oldendorf 1989, Urenjak et al. 
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1993) and decreases in its levels are consistently reported in AD patients (Parnetti et al. 
1997, Murray et al. 2014, Kantarci 2007, Shinno et al. 2007, Shiino et al. 2012, Foy et al. 
2011, Rose et al. 1999, Watanabe et al. 2010), suggesting neuronal dysfunction or death. 
Moreover, mI and NAA levels have been shown to be correlated with Aβ burden (Klunk et 
al. 1992, Murray et al. 2014) and performance in some cognitive tasks (Foy et al. 2011, Rose 
et al. 1999), implicating both in AD pathology and disease severity. 
Although, the majority of AD cases are sporadic, so far most of the animal models 
use transgenes present in the inheritable familial form. Nevertheless, these models give us 
insight into the pathological mechanisms underlying AD. Hence, here we used the human 
double mutation APPswe×PS1Δe9 mouse model to investigate inflammatory and neuronal 
integrity biomarkers as indicators of disease progression using MRS, PET, 
immunohistochemistry and cognitive assessment. 
A longitudinal study was conducted in male TG APPswe×PS1Δe9 and WT C57BL/6 mice 
to investigate neuroinflammation using PET, neurochemical profile using MRS and cognitive 
function using several behavioural assessments. This was done with the aim of 
characterising inflammatory, metabolite and cognitive differences between TG and control 
animals with age. We hypothesised that there would be increased neuroinflammation 
(demonstrated by increased DPA-714 uptake and mI levels), neuronal dysfunction 
(decreased NAA levels), neurotransmitter disturbances (altered Glu) and cognitive decline 
with age in the TG compared to WT mice. 
Methods 
Animals 
Fourteen TG male APPswe×PS1Δe9 mice (RRID: MGI:5701399) with a C57BL/6 (RRID: 
IMSR_JAX:000664) background and 17 WT C57BL/6 mice were acquired from the Jackson 
laboratory (Bar Harbor, Maine, USA) at 8 weeks of age and allocated to the study. 
Additionally, 5 WT and 7 TG mice were bred in house and complemented the initial groups 
(see details below). As the mice are per se WT or TG, the WT and TG cannot be randomized. 
All mice were kept in the Biological Sciences Facility in the University of Manchester. 
Animals were housed in individually ventilated cages in groups of 2-5 in a 12h:12h light and 
dark cycle with environmental enrichment and 24h access to food and water. In total, 22 
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male WT and 21 TG male mice were used in this study. 8 WT and 10 TG were measured 
repeatedly for MRS (2 WT and 5 TG of these were bred in house); a total of 20 WT and 16 
TG (5 WT and 7 TG of these were bred in house) mice were scanned non-repeatedly with 
PET. This was as a result of 7 TGs and 5 WTs dying of unknown causes or during anaesthesia, 
and one WT was excluded after abnormal brain morphology was noticed during MR 
imaging. In addition three animals in each group were used for analysis ex vivo at both 6 and 
12 months. At 18 months all mice were sacrificed and the brains removed for analysis ex 
vivo. All experiments were carried out in accordance with the Animal Scientific Procedures 
act 1986 and approved by the University of Manchester Local Ethical Review Committee 
Study Design 
The study was not pre-registered. Mice underwent longitudinal behavioural testing 
and imaging (Figure 1) at 6, 12 and 18 months of age (body weights (in grams, mean±SD): 
32.9±1.71, 37.9±3.45, 38.9±3.69 in WT and 34.5±3.19, 40.2±4.28, 41.1±6.17 in TG at 6m, 
12m, 18m of age respectively). Mice were also tested at 3 (11 WT and 15 TG) and 9 months 
(9 WT and 12 TG) of age to check for potential changes in behaviour and potentially guide 
changes in the choice of imaging time-points, however as there was no significant 
differences between 3, 6 and 9 months’ time-points, data from the 3 and 9 months’ time-
points are not shown here and only the time-points matching the imaging time-points are 
shown. Imaging experiments began at 6 months of age due to the development of 
detectable amyloid pathology from this age in this model (Jankowsky et al. 2004). 
Immunohistochemistry was carried out on separate animals at 6 and 12 months (see 
“animals” above). Animals followed longitudinally were culled and processed for ex vivo 
analysis at 18 months of age. A week gap was given between imaging and behavioural 
experiments to allow animals to recover from the potential stress of imaging/anaesthesia 
and limit interference between experiments. All experiments were carried out between 9am 
and 5pm, with all behaviour carried out between 9am and 2pm for each time-point. For all 
behavioural tests animals were placed in the testing room 30 minutes prior to 
experimentation to allow for habituation to the environment. 
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Behaviour 
Novel Object and Smell Recognition Tests 
A plastic circular arena (30cm diameter, 21cm height) was used for behavioural 
testing. Animals were subjected to two days of habituation and one day of novel object 
recognition (NOR) testing. Habituation involved single mice exploring an empty arena for 
5min and was carried out in a random order within the same time-frame each day. NOR 
utilizes the natural behaviour of rodents to explore novelty to test non-associative working 
memory (Ennaceur & Delacour 1988). This was assessed by investigating the ability to 
discriminate between novel and familiar objects and was carried out in both TG and WT 
mice at 6, 12 and 18 months of age. Small plastic objects of varying shapes and colours (e.g. 
Lego blocks) were used as NOR objects. Test day consisted of two phases. In phase 1, a 
mouse was placed in the arena with two identical unfamiliar objects for 10min. After this 
time, the mouse was returned to its home cage and a 1h delay was implemented. In phase 
2, one familiar object was replaced by a novel object and the mouse was given 4min to 
investigate the objects. 
Novel smell recognition (NSR) utilizes the natural exploration of novelty to test 
working memory in rodents although through olfaction. The experimental design was the 
same as the NOR, however a 3min delay was implemented and identical plastic scent balls 
with sniffing holes were stuffed with cotton wool and filled with 0.5ml of a certain scent 
(e.g. vanilla) were used. 
For both the NOR and NSR, behaviour was recorded and analysed retrospectively. In 
addition, in between trials all objects and areas were cleaned with 70% ethanol to remove 
any scent of the previous mouse which may alter results. 
Time spent investigating left and right identical objects/smells in phase 1 were 
analysed to assess side bias. Mice were to be excluded if significant side bias (> 60% of time 
spent investigating one of two identical objects) was observed in phase 1. Time spent 
exploring the novel and familiar objects in phase 2 was used to generate a discrimination 
index (DI), defined as the difference between time spent exploring the novel (Tn) and the 
familiar (Tf) object/scent divided by the total time (T) (DI=(Tn-Tf)/T). This resulted in values 
ranging from -1 to +1. A negative value indicated more time spent with the familiar, a 
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positive value indicated more time investigating the novel and a zero value indicated no 
preference. 
The re-use of novel objects for each mouse was kept to a minimum to prevent 
potential memorisation of objects/scents between time-points and ensure the test was 
unique (i.e. a truly novel object or smell they were never exposed to before). The only 
exception to this was a small cohort of mice that underwent behavioural testing at 3 months 
of age to investigate whether early time-points were needed for baseline. No significant 
differences were observed at this age in this small group and therefore only 6, 12 and 18 
months were chosen going forward with behavioural testing. 
Y-maze spontaneous alteration task 
The Y-maze spontaneous alteration task utilizes the natural exploratory behaviour of 
rodents to assess spatial learning and short-term memory. The Y-maze test was carried out 
as described previously shown by Martins et al. (2017). A black Perspex maze with 3 arms 
(15cm length x 10cm width x 10cm depth per arm) labelled with A-C and with different 
internal visual cues was used. The mice were placed inside the maze and arm entries were 
recorded manually over an 8min time period, with entries only valid if the whole body of the 
mouse entered the arm. Successful spontaneous alternation was defined by consecutive 
entry into all 3 arms in any order. Analysis was carried out by calculating overlapping triplet 
sets relative to successful arm entries as previously described (Knight et al. 2014, Hiramatsu 
et al. 1997). Percentage of successful alternation was compared between WT and TG mice 
at all ages. 
Behaviour to predator and non-predator urine 
A Y maze with either predator or non-predator urine at the end of each arm was 
used to assess the general olfactory ability of 12-month-old WT and TG mice. The maze had 
no visual cues. Vented containers were injected with 1ml of bobcat, fox or rabbit urine and 
were placed at the end of each arm. Mice were allowed to explore the maze for 8min and 
time (in seconds) spent in each arm was quantified. Time spent in the middle of or rearing 
on the side of the maze was not counted. Both bobcats and foxes are predators for mice, 
whereas rabbits are not, hence an increased amount of time in the arm containing rabbit 
urine would be expected in mice with intact olfaction. 
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[18F]DPA-714 PET 
Neuroinflammation was investigated using the TSPO tracer [18F]DPA-714. [18F]DPA-
714 was produced as previously described (James et al. 2008). Animals were anesthetised, 
cannulated (via tail vein) and injected with [18F]DPA-714 (12.3±1.9MBq). Respiratory rate 
and temperature were monitored throughout the experiment and body temperature was 
maintained at 37±0.5oC (BioVet® system m2m Imaging Corp., Cleveland, OH, USA). Images 
were acquired on a Siemens Inveon® PET-CT scanner using a 60 min dynamic acquisition. CT 
scans were performed prior to PET acquisition to obtain the attenuation correction map. 
The time coincidence window was set to 3.432 ns and levels of energy discrimination to 350 
keV and 650 keV. List mode data from emission scans were histogrammed into 16 dynamic 
frames (5×1 min; 5×2 min; 3×5 min and 3×10 min) and emission sinograms were normalised, 
corrected for attenuation, scattering and radioactivity decay and reconstructed using an 
OSEM3D protocol (16 subsets and 4 iterations) into images of dimensions 128 (transaxially) 
×159 (axially) with 0.776×0.776×0.796 mm voxels. The PET images segmented using the 
local means analysis method and the organ mean time activity curves were corrected for 
partial volume effect as previously described (Boutin et al. 2013, Maroy et al. 2008, Maroy 
et al. 2010). The correction method combined the geometric transfer matrix (GTM) method 
and the regions of interest (ROI)-opt method. Dynamic PET images were analysed using 
Brainvisa and Anatomist software (http://brainvisa.info/web/index.html) and quantified 
using Waxholm space created by Johnson et al. (Johnson et al. 2010). This MRI mouse brain 
template was used to create 3 brain ROIs (all cortical areas & whole hippocampus, 
subcortical regions and cerebellum) large enough to be accurately quantified based on the 
spatial resolution of the PET scanner (Supplementary Figure 1a-c). Data are expressed as 
uptake values normalised to the cerebellum (NUVcb) as previously used in the same mouse 
model (Serriere et al. 2015). 
Magnetic Resonance Spectroscopy Acquisition and Analysis 
Animals were anesthetised using isoflurane (3% induction and 1-2% maintenance) 
and medical oxygen at a rate of 2 L/min. Respiratory rate and temperature were monitored 
throughout the experiments which were conducted using a 7 Tesla magnet connected to a 
Bruker Avance III console (Bruker Biospin Ltd, UK). An anatomical multi-slice FLASH MRI 
sequence was used to enable positioning of the hippocampal volume for MRS. Spectra were 
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acquired using a water-suppressed PRESS sequence (Bottomley 1987) (TR 2500ms, TE 20ms, 
512 averages) from a 2.5x4.5x3 mm3 voxel that covered the hippocampus and the most 
dorsal part of the thalamus (Supplementary Figure 1d). Prior to acquiring the spectrum the 
localized voxel was shimmed using ‘FASTMAP’ (Gruetter 1993) and water suppression was 
optimized using VAPOR (Griffey & Flamig 1990). A non-water-suppressed reference PRESS 
spectrum was also acquired (1 average). 
A metabolite basis-set was simulated using NMRScope with the same spectroscopic 
parameters used for the PRESS acquisition (jMRUI version 5) (Stefan et al. 2009). 
Metabolites included in the basis-set were: NAA, Glu, mI, Cre, GABA, scyllo-inositol (Scy-I), 
Gln, Tau and tCho. Peaks at 0.9 and 1.3ppm were included to model lipid/macro-molecules. 
Another additional peak was added at 3.76ppm to cover the detection of α-protons of 
amino acids (AAP) not otherwise included in the basis set. These additional peaks were 
added to help with spectral fitting as significant residual signal had previously been found at 
these resonances (Forster et al. 2013). An example of an in vivo spectrum with labelled 
metabolites is shown in supplementary Figure 1e. Spectra were pre-processed by applying a 
HLSVD (Hankel Lanczos Singular Values Decomposition) filter to supress the residual water 
signal (van den Boogaart et al. 1994). Metabolite concentration in vivo was measured using 
the jMRUI version 5 algorithm QUEST (Ratiney et al. 2005). QUEST compiles the metabolite 
theoretical signals into a basis-set, and then fits the signals to the spectra in vivo, allowing 
detection and measurement. QUEST was run without background handling. Results were 
referenced to Cr. Referenced data was used to compare metabolite levels in WT compared 
to TG mice. 
Tissue Collection and Immunohistochemistry 
Immunohistochemistry was carried out on TG and WT animals (n=3-5) to visualise 
CD11b (microglial marker), GFAP (astroctyic marker), TSPO, 6E10 (Aβ marker), SVA2 
(synaptic vesicle marker), MAP2 (microtubule marker) and NeuN (neuronal marker). Animals 
were culled by isoflurane overdose confirmed by cervical dislocation. The brains were 
collected, snap frozen using isopentane on dry ice and stored at -80°C. Coronal brain 
sections (20µm thick), from the rostral to caudal part of the brain, were taken using a 
cryostat (Leica CM3050s, Leica Biosystems Nussloch GmbH, Germany) and stored at -80°C. 
Sections were allowed to defrost and dry at room temperature for 20min and then fixed 
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with 4% paraformaldehyde for 10min before being washed (6×5min) in phosphate buffered 
saline (PBS) and incubated for 30 minutes in 2% normal donkey serum and 0.1% Triton X-
100 in PBS to permeabilize and block non-specific binding. TSPO, 6E10, SV2A and 
neurogranin immunohistochemistry required an extra step of antigen retrieval done by 
incubating the slides in 10mM citrate buffer at 90°C for 20min and then washed 2×3 min in 
PBS. Primary antibody incubation was carried out overnight at 4°C with one of the following 
primary antibodies in 2% normal donkey serum and 0.1% Triton X-100 in PBS: rat anti-
mouse CD11b (AbD Serotec (MCA711), RRID: AB_321292, 1:1000); rabbit anti-mouse TSPO 
(Abcam (EPR5384), RRID: AB_10862345, 1:250); rabbit anti-mouse GFAP (DAKO (Z0334), 
RRID: AB_10013382, 1:1000); mouse anti-human 6E10 amyloid (BioLegend (803001),  RRID: 
AB_2564653, 1:1000); rabbit anti-mouse SV2A (Abcam (ab32942), RRID: AB_778192, 1:500); 
chicken anti-mouse MAP2 (Abcam (ab5392), RRID: AB_2138153, 1:1000); rabbit anti-mouse 
NeuN (Abcam (ab177487), RRID: AB_2532109, 1:500); rabbit anti-mouse Neurogranin 
(Abcam (ab23570), RRID: AB_447526, 1:500). Following incubation in primary antibody, PBS 
washes were repeated (3×10min) and incubated with one of the following secondary 
antibodies was carried out: Alexa Fluor 594nm Donkey anti-rat IgG 1:500 (for CD11b); Alexa 
Fluor 488nm Donkey anti-rabbit IgG 1:500 (for TSPO, GFAP, SV2A); Alexa Fluor 594nm 
Donkey anti-mouse IgG 1:500 (for 6E10); Alexa Fluor 488nm Goat anti-chicken Double 
staining was carried out for CD11b+TSPO, CD11b+GFAP and 6E10+TSPO and to allow the 
visualisation of microglia and astrocytes with TSPO expression and Aβ burden. Double 
staining was also carried out for MAP2+NeuN to look at neuronal density. 
Images of the hippocampus and cortex were collected between bregma -2.06mm 
and -2.30mm on an Olympus BX51 upright microscope using a 10×/0.30 or 20×/0.50 
UPlanFLN objectives and captured using a Retiga 6000 Color camera through QCapture Pro 
7 Software (QImaging Inc.). Specific band pass filter sets were used to prevent bleed 
through from one channel to the next. 
Statistical analysis 
No blinding stricto sensu was performed, however animals were identified and 
recorded only using a unique code number during behavioural tests and image analysis and 
only identified as TG or WT post-analysis so that the observers could not know whether the 
animal being analysed was a WT or a TG. Sample size were calculated to n=9-10 per group 
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using anterior data obtained in our laboratory using the following online tool: 
https://www.stat.ubc.ca/~rollin/stats/ssize/n2.html (with =0.05, β=0.2, with anticipated 
mean difference of 8% and SD~5-8%). 
The data were statistically analysed using GraphPad Prism version 5.04. Behavioural 
data are expressed as mean±SEM and imaging data are expressed as mean±SD. Paired t 
tests were used to determine differences in exploration in phase 1 of both the NOR and NSR 
tests. Two way analysis of variance (ANOVA) were carried out to test the effect of strain and 
age on DI, percentage of successful alternation in the Y-maze, metabolite levels and 
[18F]DPA-714 uptake in WT and TG mice. Post-hoc analysis was carried out using Dunnet’s 
and Sidak’s tests. Main effects were considered significant if p≤0.05. Interactions were 
deemed significant if p≤0.1. Significance was not adjusted for comparisons of multiple 
region of interest as those were not compared between them, but if a Bonferoni correction 
had been applied to the DPA-714 to account for the number of regions analysed, the 
appropriate adjusted P value would be P<0.017. 
Results 
TG mice display increased cognitive decline 
To test whether short-term working and recognition memory were affected at 
different ages, Y maze and novel recognition tests were carried out (Figure 2). No significant 
differences in DI were seen between WT and TG mice in the NOR at 6 months of age (Figure 
2a). Both groups displayed positive DI results suggesting a preference for the novel and 
indicating good short-term memory at this age. However, analysis revealed a significant 
interaction between gene and age (Figure 2a, p=0.0225). This effect was due to a significant 
decrease in cognitive performance in the TG mice compared to the WT mice at 12 months 
of age as assessed by DI scores (p≤0.01). This effect was not replicated at 18 months of age, 
whereby both groups displayed low DI scores suggesting poor cognitive performance in 
both WT and TG by this age. No significant differences were seen in the exploration of 
identical objects in phase 1 of the NOR (Figure 2b) indicating that there was no side bias in 
the test. 
No significant differences in performance were seen between groups in the NSR 
(Figure 2c). At 6 months of age, both WT and TG were able to discriminate between novel 
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and familiar smell, demonstrating good working memory and olfaction. Although no side 
bias was observed in phase 1 (Figure 2d), high variation was seen in this test from 12 
months of age onwards, therefore the olfactory ability of these mice was tested at this age. 
In the olfaction test the behaviour to predator and non-predator urine was tested. Neither 
WT nor TG spent significantly more time in the arms containing rabbit urine when compared 
to fox or bobcat urine (Figure 2e) indicating olfactory dysfunction from 12 months of age. 
TG mice also displayed increased cognitive decline in the Y-maze test (Figure 2f). 
Overall decreased percentages of successful alternation were seen in the TG mice as an 
effect of gene (p=0.0001). In addition, a significant interaction was observed between gene 
and age (p=0.0233). This effect did not reveal any significant differences in Y-maze 
performance at 6 or 12 months of age. In contrast, at 18 months a significant decrease in 
the percentage of alternation was observed in TG mice compared to age matched WT mice 
(p≤0.001) indicating accelerated decline in short-term working memory in TGs at this age. 
[18F]DPA-714 binding significantly increases in vivo as a result of AD-like pathology and 
age 
To assess neuroinflammation differences between APPswe×PS1Δe9 and WT mice, 
[18F]DPA-714 NUVcb was compared at 6, 12 and 18 months in the hippocampal+cortical and 
subcortical ROIs (Figure 3a). Statistical analysis of the cerebellum standard uptake value 
(SUV) revealed a significant effect of age only, which the Sidak’s post-hoc test revealed to be 
between 6 and 18 months old WT only. No other difference, particularly between WT and 
TG, could be found in the cerebellum SUV justifying the use of the cerebellum to normalise 
the uptake values as previously done in this type of study (Serriere et al. 2015, Takkinen et 
al. 2016). A two-way ANOVA revealed a significant effects of gene (p=0.02) and age (p=0.03) 
on [18F]DPA-714 uptake in the hippocampus and cortex, which resulted in a modest but 
significant increase in [18F]DPA-714 NUVcb uptake in TG mice at 18 months of age 
(0.930±0.059) when compared to both age-matched WT (Figure 3b, 0.870±0.044; +7%, 
p=0.04) and 6-month-old TG mice (0.866±0.051; +7%, p=0.03). These results suggest that 
both age and disease increase the neuroinflammatory status of TG mice. An increasing 
effect was seen with age on [18F]DPA-714 NUVcb values in the other subcortical region 
(p=0.0008) and a significant increase in [18F]DPA-714 NUVcb uptake was seen in other 
subcortical regions of 18 months old TG mice (0.638±0.034) when compared to 6 months 
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old TG mice (Figure 3b, 0.726±0.067; +14%, p=0.002). The same trend was observed in the 
subcortical regions of WTs but was not significant (Error! Reference source not found.Figure 
3c, p=0.058). 
Metabolite profiles of APPswe×PS1Δe9 and WTs are affected by age 
Single voxel 1H MRS was repeated in the same cohort of TG and WT mice at 6, 12 and 
18 months of age to investigate changes in metabolite profile. A 3×3×3 mm voxel was 
placed to encompass the hippocampus and the most dorsal part of the thalamus. Example 
spectra from this region can be seen in Figure 4a. No significant differences were seen in Cr 
concentration referenced to water at any age group for either WT or TG mice (Figure 4d), 
allowing metabolite data to be expressed as a ratio to Cr. This has been previously reported 
in this model (Jansen et al. 2013), however it was important to assess this as elevated Cr 
levels, compared to WT mice, have previously been reported in the TASTPM mouse model 
of AD in vivo at an early age (Forster et al. 2013) and at a later age analysing brain extracts in 
vitro (Forster et al. 2012). No overall significant effects of gene were seen on any metabolite 
in these animals. However, a significant effect of age (p=0.0006) and a significant interaction 
between gene and age (p=0.0866) was observed for NAA. This effect resulted in significantly 
lower NAA in 18-month-old TG mice compared to 6-month-old TG mice using multi-
comparisons analysis (-58%, Figure 4b, p≤0.0001). This aging effect was seen in the WT mice 
(-20%) but was not statistically significant. Significant aging effects were also observed on 
Glu (p=0.0003) and tCho (p=0.0016) levels, resulting in reduced Glu (-53% average across 
groups from 6 to 18 months) and increased tCho (+71% average across groups from 6 to 18 
months) levels with age. No gene effect or gene×genotype interaction was associated with 
these changes suggesting that these alterations are an effect of normal aging. 
Immunohistochemistry 
To verify the in vivo imaging results, ex vivo immunohistochemistry was performed 
to assess the presence of neuroinflammation, Aβ burden and neuronal integrity. GFAP and 
CD11b positive staining was seen in the hippocampus (Figure 5a) and cortex (Figure 5b) of 
TG mice but not WT mice. Low levels of immunostaining were evident at 6 months of age 
and increased with age in both regions in TG mice. Similarly, double staining for TSPO and 
CD11b revealed an increase in both proteins with age in the hippocampus (Figure 6a) and 
cortex (Figure 6b) of the TG mice. In the TG mice, there was regional co-expression of TSPO 
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and CD11b in the hippocampus and cortex, with a modest expression at 6 months of age 
increasing at 12 months and further at 18 months. In WT animals, TSPO staining was only 
seen in the vessels and not the parenchyma in both regions. No CD11b staining was evident 
in the WTs at any age. Immunostaining for TSPO and Aβ pathology (6E10) revealed similar 
results. An age dependent increase was seen in Aβ burden in both the hippocampus (Figure 
7a) and cortex (Figure 7b) of TG mice only. Aβ staining was sparse at 6 months but increased 
with age revealing a heavy burden by 18 months. CD11b, TSPO and 6E10 demonstrated 
good regional co-expression from 6 to 18 months in the cortex of TG mice, indicating 
increased microglial activation around Aβ plaques. No Aβ staining was evident in the WT 
mice at any age. No differences were seen in staining for MAP2, NeuN (Figure 8a-b) and 
SV2A and neurogranin (Figure 9a-b) between TG and WT mice or with age in the 
hippocampus or cortex indicating that neuronal death could not be detected in this model 
with this method. 
Discussion 
In vivo studies 
Cognitive performance in the TG group at 6 months of age was comparable to WT 
mice and has been previously reported in a variety of memory based tests in this (Chen et 
al. 2012, Jansen et al. 2013) and other AD models (Webster et al. 2013, Nagakura et al. 
2013). This supports the low levels of Aβ load observed at this age in this and other studies 
(Jankowsky et al. 2004, Garcia-Alloza et al. 2006). TG mice displayed deficits in non-
associative recognition memory and working memory from 12 months, with reduced 
cognitive performance in the NOR test and Y maze by 12 and 18 months respectively. 
Cognitive deficits in these tests have been previously reported in both this (Petrov et al. 
2015) and other amyloid based models of AD (Martins et al. 2017, Daniels et al. 2016, 
Forster et al. 2013), further supporting the link between pathology burden and cognitive 
decline. WT mice retained memory later in both tests, displaying increased working memory 
in the Y-maze test compared to TG at 18 months. However, no differences in cognition were 
identified in the NSR test. Both WT and TG were able to discriminate between novel and 
familiar scents at 6 months of age, demonstrating good working memory and olfaction. 
However, high variation in both groups was observed in this test from 12 months onward, 
therefore we hypothesised that these animals may have altered olfaction by this age, which 
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was proven by the lack of preference of exposure to non-predator (rabbit) urine over 
predator (bobcat and fox) urine. An increased amount of time in the arm with non-predator 
urine would be expected in mice with intact olfaction; hence this result suggests may be 
down to reduced olfaction rather than cognitive deficit. These results are in part in line with 
previous publications showing various alterations of olfaction in Tg2576 (Wesson et al. 
2011) and in APPswe×PS1Δe9 mice (Yao et al. 2016) using different tests and with clinical 
reports showing that loss of olfaction is common in neurodegenerative diseases and is an 
early sign of AD (Mesholam et al. 1998). We however also observed a loss of olfaction in our 
WT mice. Similarly, some previous studies reported early cognitive dysfunction prior to 
pathology development using different behavioural assessments such as the Morris water 
maze (Zhang et al. 2012). Here we report decline in memory with age in APPswe×PS1Δe9 mice, 
which is in support of our working hypothesis that cognitive performance decreases with 
age at a faster rate in the TG mice compared to the WT. 
It has been hypothesized that neuroinflammation precedes clinical manifestation of 
cognitive dysfunction in AD. In this study, we observed the presence of neuroinflammation 
in TG mice via immunohistochemistry (CD11b and GFAP) from 6 months which increased 
with age. However, increased neuroinflammation and altered metabolite profile, assessed 
via in vivo PET and MRS respectively, occurred after the emergence of cognitive decline in 
this animal model. 
Increased [18F]DPA-714 NUVcb was found in the hippocampal and cortical region of 
old TG mice when compared to both age matched WT mice and young TG mice, suggesting 
that increased neuroinflammation in hippocampal and cortical region is driven by the 
presence of AD pathology in TG mice. This increase was only statistically significant at 18 
months of age despite increased Aβ, GFAP and CD11b immunostaining evident from 12 
months of age. Although a significant increase is also seen with age in [18F]DPA-714 uptake 
in the other subcortical regions, no significant differences were found between genotypes. A 
trend towards significance was also observed in the WTs in the subcortical ROI. As these 
regions have little to no amyloid burden, these data suggest that neuroinflammation in 
these regions is increased mostly as a result of normal aging and independently of amyloid 
pathology. It is however notable that Yokokura et al. recently reported increased uptake in 
the thalamus of AD and elderly patients using [11C]DPA-713 (Yokokura et al. 2017). These 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
results suggest that neuroinflammation is present prior to cognitive dysfunction, however 
current in vivo methods are not sensitive enough (due to a combination of tracer sensitivity, 
resolution capabilities of small animal PET and non-specific relevance of the mI signal) to 
detect the more subtle inflammatory changes in the earlier stages of disease that are 
achievable via ex vivo methods. 
Our data are in agreement with previous reports in mouse models using [18F]DPA-
714. Serriere et al. investigated [18F]DPA-714 uptake in the same mouse model at 6, 9, 12, 
15 and 19 months of age (Serriere et al. 2015). NUVCb were increased in the cortex of TG 
mice at 12 and 19 months (but not 15 months of age) and in the hippocampus at 19 months 
of age. Increased cortical [18F]DPA-714 NUVcb has also been reported in the APP/PS1-21 
mouse from 6 months of age, with hippocampal increases emerging from 12 months of age 
(Takkinen et al. 2016). In our analysis methods, we pooled cortical and hippocampal areas 
as one region due to AD pathology present in both regions and because the size of the 
pooled ROI is more realistically compatible with the resolution of PET imaging in preclinical 
scanners (~1-1.6mm). Therefore, by pooling the hippocampus and cortex into a single ROI, 
we may have masked the possible differential time-effect between each region, and hidden 
the earlier increase in neuroinflammation in the cortex. However, such difference would be 
small as our immunohistochemistry results show only a slightly stronger signal in CD11b and 
TSPO in the cortex than in the hippocampus in this model at 6 and 12 months of age. On the 
other hand, it can also be argued that thin ROIs including only the cortical hippocampal 
areas (~1.5mm thick) are far more subject to partial volume effects, which could 
consequently have biased the quantification in previous studies. A significant effect of both 
age and gene on TSPO PET has been also recently reported in the same model using [18F]GE-
180 (Liu et al. 2015). Increased [18F]GE-180 uptake was seen in the hippocampus of old TGs 
compared to age matched WTs and young TG and WT mice. In addition, increased [18F]GE-
180 uptake was also seen in the whole brain of old TGs compared to young TGs. This age 
effect was replicated in WT mice with significant increases in uptake from young to old mice 
in both hippocampal and whole brain, implicating both normal aging and AD pathology on 
neuroinflammatory status. Increased neuroinflammation has also been observed as an 
effect of aging in both humans (Kumar et al. 2012, Yokokura et al. 2017, Gulyas et al. 2011) 
and in the WTs of other AD models (Brendel et al. 2016). Altogether, our results further 
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support previous findings that age can significantly alter microglial responses, which are 
modified further in the presence of neurodegenerative diseases such as AD. Increases in 
TSPO expression have been found in other models of AD (James et al. 2015, Brendel et al. 
2016, Ji et al. 2008, Mirzaei et al. 2016) and in human AD (Varnum & Ikezu 2012, Rubio-
Perez & Morillas-Ruiz 2012, Swardfager et al. 2010, Forlenza et al. 2009), indicating that 
elevated neuroinflammation is a consistent characteristic of this disease. The modest 
increases and the relative overlap between WT and TG mice demonstrated by the present 
data and others’ are also in agreement with the PET quantification in AD patient vs healthy 
controls which generally reports non-significant (Varrone et al. 2013) or small to more 
substantial increases (+10-35%) (Schuitemaker et al. 2013, Hamelin et al. 2016, Okello et al. 
2009, Edison et al. 2008, Varrone et al. 2015) in neuroinflammation. This demonstrates that 
i) measuring neuroinflammation in vivo in AD is challenging because the amplitudes of 
changes are overall modest when compared with the changes induced by ageing only and ii) 
that, at least from this point of view, animal models are actually reflecting the clinical 
situation quite well. Finally, a recent study by Owen et al. (Owen et al. 2017) suggests that, 
at least in human, TSPO expression may reflect microglia density rather than microglia 
phenotype. Although obtained from a purely in vitro setting in which cells may behave 
differently than in their in vivo environment, these observations taken together with the 
known TSPO expression by endothelial cells may explain the inconsistencies between 
imaging studies and the difficulties encountered over the years to truly assess microglial 
activation in AD patients using TSPO PET. 
In contrast to increased neuroinflammation assessed by PET and 
immunohistochemistry, no alterations in mI levels were observed between TG and WT mice 
in this study. This lack of agreement between neuroinflammatory status and mI expression 
questions the role of mI as a putative marker for gliosis with the specific biological 
significance of mI needing further investigation to be truly elucidated. In support of this, 
reported mI level alterations are inconsistent in this model, with both increased and stable 
levels reported (von Kienlin et al. 2005, Dedeoglu et al. 2004, Jansen et al. 2013). Moreover, 
in a clinical study mI was found to be associated with amyloid pathology and not 
neuroinflammation (Murray et al. 2014), therefore it is possible that mI levels represent 
more closely amyloid load than neuroinflammation. On the other hand we have extensive 
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amyloid burden in this model without seeing mI alterations. These results are in contrast to 
many other reports demonstrating increased mI levels in clinical AD (Foy et al. 2011, Shiino 
et al. 2012, Murray et al. 2014, Kantarci et al. 2007, Shinno et al. 2007) and AD models 
(Chen et al. 2009, Chen et al. 2012, Marjanska et al. 2005, Jack et al. 2007, Oberg et al. 2008, 
Choi et al. 2014, Choi et al. 2010, Marjanska et al. 2014, Yang et al. 2011, Forster et al. 
2013). Chen et al. reported significantly higher mI/Cr levels in the APPswe×PS1Δe9 compared 
to WT mice as early as 3 months of age (Chen et al. 2009). However the voxel used in this 
study included cortical as well as hippocampal tissue. Here we report the appearance of 
inflammation and plaques in cortical regions prior to and more frequently than in 
hippocampal regions, so the discrepancies between studies might be due to differences in 
size and location of the voxel used as well as the age studied. 
Although no qualitative changes were observable in neuronal markers (MAP2 and 
NeuN) using immunohistochemistry, a significant effect of aging and a significant 
genotype×age interaction was observed on NAA levels, resulting in a -58% decrease in 
NAA/Cr in 18 months old TG mice when compared to 6 months old TG. This effect was not 
mirrored in the WT mice and suggests that decreased NAA levels, although influenced by 
both age and gene, are slightly more pronounced in TG mice. This underlines the 
importance of understanding the pattern of normal aging within brain metabolites or other 
potential biomarkers and the possible confounding effects of age. 
Chen et al. reported a small but significant decrease (-11% change, 1.16±0.07 in WT 
vs 1.03±0.06 in TG) in NAA/Cr from 5 months of age (Chen et al. 2009). In contrast, we 
report NAA alterations post-cognitive decline and is in line with the results from Xu et al. in 
the same animal model (Xu et al. 2010). Xu et al. found a significant decrease in 
hippocampal NAA/Cr in 16 month APPswe×PS1Δe9 TG mice compared to younger TG mice, 
which was not seen in WT mice. Similar decreases in NAA/Cr associated with age and AD 
pathology have been reported in other models of AD, at varying ages (Jansen et al. 2013, Xu 
et al. 2010, Jack et al. 2007, Forster et al. 2013, Choi et al. 2010, Oberg et al. 2008, 
Marjanska et al. 2005, Choi et al. 2014). We also report age to have a significant effect on 
Glu and tCho levels without an effect of genotype effect or an interaction genotype×age, in 
which Glu levels were decreased and tCho levels increased in both WT and TG mice. 
Similarly, specific reduced Glu and increased tCho levels have been reported in mouse 
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models of AD (Marjanska et al. 2005, Jack et al. 2007, Chen et al. 2012, Oberg et al. 2008, 
Dedeoglu et al. 2004, Choi et al. 2010, von Kienlin et al. 2005, Esteras et al. 2012) and in the 
clinical situation (Shiino et al. 2012, Hattori et al. 2002, Kantarci 2007, Foy et al. 2011, 
Griffith et al. 2008) vs WT or healthy controls respectively. This result suggests that these 
effects are a result of normal aging in this strain. 
Ex vivo immunohistochemistry 
 To verify the in vivo imaging results, ex vivo immunohistochemistry was performed 
to assess the presence of microglia, astrocytes, TSPO expression and Aβ pathology. Aβ 
pathology was sparse in young TG mice with increasing burden evident by 12 months and 
abundant plaques by 18 months. This level of Aβ burden is line with many previous reports 
in this model (Garcia-Alloza et al. 2006, Jankowsky et al. 2004, van Groen et al. 2006). 
Similarly, low levels of CD11b, GFAP and TSPO staining were evident in the hippocampus 
and cortex of TG mice at 6 months, which increased with age. Co-localisation of CD11b and 
TSPO was observed in the cortex and the hippocampus, confirming that in this model TSPO 
is mostly expressed by microglia. Similarly, TSPO and Aβ co-localisation was observed in the 
cortex of TG mice, indicating increased glial activation around Aβ plaques. Similarly, strong 
astrogliosis was detected around microglial cells which were found only around Aβ plaques 
supporting the presence of both astrocytes and microglia around Aβ plaques. Microglial 
cells are known to surround plaques in human AD and have been shown to co-localize with 
pathology in AD models further supporting the role of neuroinflammation in AD. In contrast 
to our results, Ji et al., did not find co-expression of CD11b and TSPO in the APP23 mouse 
model, but found co-localisation of GFAP and TSPO which were in close proximity to amyloid 
plaque staining (Ji et al. 2008). Whereas the opposite was identified in a tau model, with 
CD11b but not GFAP positive cells expressing TSPO. These results suggest that different 
forms of tau and amyloid pathology may alter TSPO expression differently in vivo (Jansen et 
al. 2013). This may be due to potential differences in type of amyloid, aggregation 
properties, expression levels, and age of pathology emergence between different models of 
AD, which may differently affect the glial response (Stalder et al. 1999, Xiong et al. 2011, 
Huang et al. 2016). In contrast, TSPO expression was only visible in the vessels in WT 
animals which are in agreement with previous report demonstrating the expression of TSPO 
in vessels (Turkheimer et al. 2007). 
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We did not identify any striking reductions in neuronal, synaptic vesicle or 
microtubule markers in this study. This is in line with previous reports (Jansen et al. 2013) 
suggesting that APP mutations are not sufficient to cause neuronal loss that is observed in 
human AD and models with tau abnormalities but in contrast with Huang et al. who 
reported a decrease (~20%) in NeuN staining and hippocampal atrophy (~20-30%) (Huang et 
al. 2016). On the other hand amyloid pathology induced cognitive decline and resulted in 
accelerated NAA loss with age in TG compared to WT mice. This lack of congruency could be 
explained by many factors such as assessing the wrong neuronal/synaptic markers, changes 
being too small or regionally specific or as a result of changes in certain neuronal 
populations (e.g cholinergic) to be detectable using the methods and markers used here. 
Conclusion 
It has become evident that Alzheimer’s disease is a complex multi-factorial disease in 
which neuroinflammation plays a pivotal role. In support of this, we report increased 
neuroinflammation in the form of increased [18F]DPA-714 uptake, confirmed through the 
use of immunohistochemistry, and reduced neuronal function in the form of accelerated 
NAA reductions in the APPswe×PS1Δe9 similar to those measured in AD patients. We here 
show that TSPO PET can detect changes in neuroinflammation in this mouse model, 
however not as early as detected using ex vivo techniques. This suggests that, although 
TSPO PET is a viable imaging technique to study AD in animal models, the current 
restrictions due to resolution and brain size in mice hamper earlier detection. Moving to 
larger species such as rats may address this. Overall, these results support the role of 
neuroinflammation in the pathogenesis of AD and the potential use of metabolite alteration 
to monitor disease progression or response to treatments. 
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List of abbreviations 
AD Alzheimer's disease 
Aβ β-amyloid plaques 
CD11b integrin αM chain of the Macrophage-1 antigen 
CSF cerebrospinal fluid 
Cr creatine & phosphocreatine 
DI discrimination index 
Tf Time spent exploring the familiar object/scent 
GFAP Glial fibrillary acidic protein 
Glu glutamate 
MRS magnetic resonance spectroscopy 
MAP2 Microtubule-associated protein-2 
MCI mild cognitive impairment 
MR magnetic resonance 
mI myo-inositol 
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NAA N-acetylaspartate 
NFTs neurofibrillary tangles 
NUVcb normalised (to the cerebellum) uptake value  
NOR novel object recognition 
NSR Novel smell recognition 
PET positron emission tomography 
SUV standard uptake value 
SVA2 Synaptic vesicle glycoprotein 2A 
Taur taurine 
Tn time spent exploring the novel object/scent 
tCho total choline 
T total time exploring objects/scents 
TG Transgenic 
TSPO translocator receptor 18kDa 
WT wild type 
 
Figure Legends 
Figure 1: Gantt chart of the study. Behaviour tests and PET and MRS scans were 
performed at 6, 12 and 18 months of age. Behaviour tests were also performed at two 
additional time-points to evaluate potential cognitive changes and would cognitive deficit 
been detected at 9 months the imaging time-points would have been brought forward. 
Figure 2: Discrimination index (DI) of exploration of the novel and the familiar object (a) and 
smell (c) in phase 1 and 2 (WT n=11, TG=15 at 6 months, WT n=6, TG=9 at 12 months, WT 
n=6, TG=6 at 18 months). Exploration times of right and left objects in phase 1 of the NOR 
(b) and NSR (d) (t-tests per genotype at each age). Time spent in the presence of predator 
and non-predator urine (n=4) (e). Alternation in the Y-maze (WT n=16, TG=18 at 6 months, 
WT=12, TG=11 at 12 months, WT=9, TG=10 at 18 months) (f). Results are shown as 
mean±SEM. Statistical analysis was performed using two-way ANOVAs and Sidak’s multiple 
comparisons post-hoc tests (***p≤0.001). 
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Figure 3: PET images showing [18F]DPA-714 uptake in WT and APPswe×PS1Δe9 mice at 6 (WT 
n=10, TG=7), 12 (WT n=8, TG=9) and 18 months (WT n=10, TG=9) of age (a). NUVcb values in 
the hippocampus and cortex (b) and other subcortical regions (c). Results are expressed as 
mean±SD. Statistical analysis was performed using two-way ANOVA followed by Sidak’s and 
Dunnet’s post-hoc analysis (*p≤0.05, **p≤0.01). 
Figure 4: Example spectra from WT and TG mice at 6, 12 and 18 months (a). Metabolites 
expressed as ratios to creatine in WT (n=6) (b) and TG (n=8) (c) mice at 6, 12 and 18 months 
of age. No differences were observed in the Cr concentration (mean±SD) referenced to 
water (d). Reduced Glu/Cr and increased tCho levels were observed with age in both WT 
and TG (independently of genotype). Results are shown as mean±SD. Statistical analysis was 
performed using two-way ANOVA followed by Dunnet’s post hoc analysis. ( ****p≤0.0001). 
Figure 5: Immunoreactivity of GFAP (green) and CD11b (red). Representative images of 
double staining in the hippocampus (a) and cortex (b) of WT and APPswe×PS1Δe9 mice at 6, 12 
and 18 months of age. Pictures were taken at 10× magnification between bregma -2.06mm 
and -2.30mm. Scale bar represents 200µm. 
Figure 6: Immunoreactivity of TSPO (green) and CD11b (red). Representative images of 
double staining in the hippocampus (a) and cortex (b) of WT and APPswe×PS1Δe9 mice at 6, 12 
and 18 months of age. Pictures were taken at 10× magnification between bregma -2.06mm 
and -2.30mm. Scale bar represents 200µm. 
Figure 7: Immunoreactivity of TSPO (green) and Aβ (red). Representative images of double 
staining in the hippocampus (a) and cortex (b) of WT and APPswe×PS1Δe9 mice at 6, 12 and 18 
months of age. Pictures were taken at 10× magnification between bregma -2.06mm and -
2.30mm. Scale bar represents 200µm. 
Figure 8: Immunoreactivity of MAP2 (green) and NeuN (red). Representative images of 
double staining in the hippocampus (a) and cortex (b) of WT and APPswe×PS1Δe9 mice at 6, 12 
and 18 months of age. Pictures were taken at 10× magnification between bregma -2.06mm 
and -2.30mm. Scale bar represents 200µm. 
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Figure 9: Immunoreactivity of neurogranin (red) and SV2A (green). Representative images of 
single SVA2 staining in the hippocampus (a) and cortex (b) and neurogranin staining in the 
hippocampus (c) and cortex (d) of WT and APPswe×PS1Δe9 mice at 6, 12 and 18 months of 
age. Pictures were taken at 10× magnification between bregma -2.06mm and -2.30mm. 
Scale bar represents 200µm. 
Supplementary figure 1: Whole brain was segmented into the hippocampus and cortex (a), 
other subcortical (b) and cerebellum (c) regions of interest for PET quantification using a 
modified version of the Waxholm space template (Johnson et al. 2010). The MRS voxel was 
centred at bregma -2.30mm according to the Paxinos mouse brain atlas and encompassed 
hippocampal and thalamic regions (d). Example of an MRS spectrum in vivo with the main 
metabolites highlighted (e). AAP-amino acid proton, mI-myo-Inositol. Tau-taurine, Cho-
choline containing compounds, Cre- creatine+phosphocreatine, Glu- glutamate, GABA- γ-
aminobutyric acid, NAA- N-acetylaspartate, Lipid MMS- lipid and macromolecules. 
Supplementary figure 2: [18F]DPA-714 standard uptake value in the cerebellum of WT and 
APPswe×PS1Δe9 mice at 6 (WT n=10, TG=7), 12 (WT n=8, TG=9) and 18 months (WT n=10, 
TG=9) of age. Results are expressed as mean±SD. Statistical analysis was performed using 
two-way ANOVA followed by Sidak’s post-hoc analysis (*p≤0.05). 
Supplementary figure 3: Immunoreactivity of GFAP (green) and CD11b (red). Representative 
images of double staining in the hippocampus (a) and cortex (b) of WT and APPswe×PS1Δe9 
mice at 6, 12 and 18 months of age. Pictures were taken at 20× magnification between 
bregma -2.06mm and -2.30mm. Scale bar represents 200µm. 
Supplementary figure 4: Immunoreactivity of TSPO (green) and CD11b (red). Representative 
images of double staining in the hippocampus (a) and cortex (b) of WT and APPswe×PS1Δe9 
mice at 6, 12 and 18 months of age. Pictures were taken at 20× magnification between 
bregma -2.06mm and -2.30mm. Scale bar represents 200µm. 
Supplementary figure 5: Immunoreactivity of MAP2 (green) and NeuN (red). Representative 
images of double staining in the hippocampus (a) and cortex (b) of WT and APPswe×PS1Δe9 
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mice at 6, 12 and 18 months of age. Pictures were taken at 20× magnification between 
bregma -2.06mm and -2.30mm. Scale bar represents 200µm. 
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